Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.39 |
| ▸ | DRD4 | P21917 | 8/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | DRD3 | P35462 | 4/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16250669 | 0.86 | DRD4 (0.45) | FFAR4DRD4DRD2DRD3ADRA1D | |
| SCHEMBL238412 | 0.83 | GRM2 (0.41) | FFAR4DRD4DRD2DRD3CHRM2 | |
| SCHEMBL16249188 | 0.80 | SLC18A3 (0.43) | DRD2GRM2 | |
| SCHEMBL16249190 | 0.74 | DRD2 (0.48) | FFAR4DRD2 | |
| SCHEMBL16218248 | 0.72 | CHRM2 (0.47) | KDM5ADRD4DRD2DRD3CHRM2 | |
| SCHEMBL16788907 | 0.72 | SLC6A2 (0.37) | FFAR4DRD2ALDH1A1MAPT | |
| SCHEMBL171599 | 0.70 | DRD4 (0.48) | DRD4DRD2DRD3CHRM2CHRM4 | |
| SCHEMBL29352448 | 0.70 | DRD4 (0.48) | DRD4DRD2DRD3CHRM2CHRM4 | |
| SCHEMBL16249199 | 0.70 | CYP2D6 (0.33) | FFAR4 | |
| SCHEMBL27358364 | 0.69 | FFAR4 (0.35) | FFAR4DRD3CHRM2CHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232455-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150158909-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150126747-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-05-07 | — | — | US | disclosed |
| US-20150105548-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150065542-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150031884-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140364617-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2014-12-11 | — | — | US | disclosed |
| US-20140364616-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (IL) | 2014-12-11 | — | — | US | disclosed |
| US-20140343286-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031884-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | KDM5A 3365/4885FFAR4 4220/4885DRD4 2753/4885 |
| US-20140364616-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | KDM5A 3365/4885FFAR4 4220/4885DRD4 2753/4885 |
| US-20140343286-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | KDM5A 3365/4885FFAR4 4220/4885DRD4 2753/4885 |
| US-20150105548-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | KDM5A 3365/4885FFAR4 4220/4885DRD4 2753/4885 |
| US-20150232455-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | KDM5A 3365/4885FFAR4 4220/4885DRD4 2753/4885 |
| US-20140364617-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | KDM5A 3365/4885FFAR4 4220/4885DRD4 2753/4885 |
| US-20150126747-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | KDM5A 3365/4885FFAR4 4220/4885DRD4 2753/4885 |
| US-20150065542-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | KDM5A 3365/4885FFAR4 4220/4885DRD4 2753/4885 |
| US-20150158909-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | KDM5A 3365/4885FFAR4 4220/4885DRD4 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.